WHO 1st International Standard for MOLT-4 Cancer Genome
This product is a highly characterised single batch cancer genomic DNA (gDNA) International Standard covering the TP53 p.R306*, NRAS p.G12C, PTEN p.K267fs*9, and MAP2K1/MEK1 p.D67Nclinically-relevant variants. The standard is provided at the consensus variant percentage shown in the table below and may be diluted using the WHO 1st International Standard for ATDB102 Reference Genome (18/164) or another wild-type gDNA aligned to 18/164 to generate standards at a range of variant percentages which enable the calibration of quantitative assays.
Additionally, information about the TP53, NRAS, PTEN, and MAP2K1/MEK1variant and total gene copy number per diploid human genome mass is given.
The International Standard was established by the WHO ECBS following an extensive collaborative study involving 35 laboratories across 22 countries and 5 continents and it is suitable for any NGS (Next Generation Sequencing) and dPCR (digital PCR) analysis.
Product details
- Contents: ~5µg freeze-dried gDNA
- Source cell line: MOLT-4
- Human tissue source: Acute T cell lymphoblastic leukaemia
|
NIBSC material code
|
Nominal variant
|
Consensus variant percentage (%)
|
Consensus variant copy number per diploid human genome mass
|
Consensus total copy number per diploid human genome mass
|
Genomic coordinates
|
|---|
| 18/130 |
TP53 c.916C>T (R306*) |
31.8 |
0.48327 |
1.52050 |
17:7577022-7577022 |
| NRAS c.34G>T (G12C) |
24.7 |
0.45954 |
1.85863 |
1:115258748-115258748 |
| PTEN c.795delA (K267fs*9) |
100** |
1.78544 |
1.78545 |
10:89717769-89717769 |
MAP2K1/MEK1
c.199G>A (D67N) |
25.3 |
0.44476 |
1.75702 |
15:66727483-66727483 |
** Wild-type calculated as 0.00001% but likely to be 0 therefore consensus variant percentage shown as 100%.
Additional information
-
Additional variants identified in the standard during the collaborative study demonstrate suitability for the broader validation of any NGS pipeline. For details, click here.
-
The gDNA size fractionation profiles of this material indicates compatibility with long read sequencing approaches.
-
Interactive dilution curve
-
Product Instructions for Use (IFU)
-
We are working closely with the Genomics England Ltd R&D Team and the Medical Genomics- Glasgow Precision Oncology Laboratory to further characterize this material for long read sequencing and whole genome sequencing (WGS).
How to order
To place an order please log in to your account or sign up for a new account.
For more information on our International Standards for oncogene variant detection contact grmteam@nibsc.org.